The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Valuation Is Forecasted For The Anti-Parkinson Drugs Market By 2030 Starting From Its 2026 Size?
The anti-parkinson drugs market has experienced consistent growth in its scale lately. It is projected to expand from $10.96 billion in 2025 to $11.46 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.6%. This historical expansion can be attributed to an increasing aging population, a rise in Parkinson’s disease diagnoses, the sustained use of levodopa, enhancements in neurological care, and the demand for chronic disease management.
The anti-parkinson drugs market is projected to experience robust expansion over the upcoming years. This market is set to reach $14.28 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.6%. Factors contributing to this growth during the forecast period include an increase in neurodegenerative disorders, advancements in neuroprotective drug innovation, the broader availability of transdermal therapies, enhanced access to healthcare, and an emphasis on improving patients’ quality of life. Key trends anticipated in the forecast period encompass a surging demand for dopaminergic therapies, the expanding adoption of extended-release formulations, a heightened focus on managing symptoms, the proliferation of combination drug therapies, and advancements in drug delivery technologies.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3462&type=smp
What Drivers Are Shaping The Future Growth Of The Anti-Parkinson Drugs Market?
The rising occurrence of mental health disorders is anticipated to fuel the expansion of the mental wellness market. Such disorders involve a clinically significant impairment in an individual’s thinking, emotional regulation, or behavior. The increasing frequency of mental disorders stems from greater exposure to ongoing stress and difficult life events that overwhelm coping abilities and trigger psychological issues. This rise in mental disorders also expands the anti-Parkinson drugs market, as these medications assist in reducing and treating such conditions. For instance, a report from the US-based health research organization, the Institute for Health Metrics and Evaluation, stated in October 2025 that in 2023, 15% of the world’s population suffered from mental disorders, and 17% of the global years lived with disability were attributed to mental disorders in the same year. Consequently, the widespread prevalence of mental disorders is a key factor propelling the growth of the anti-Parkinson drugs market.
Which Segment Categories Define The Anti-Parkinson Drugs Market?
The anti-parkinson drugs market covered in this report is segmented –
1) By Drugs Class: Levodopa Or Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs
2) By Route of Administration: Oral, Injection, Transdermal
3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies
Subsegments:
1) By Levodopa Or Carbidopa: Immediate-Release Levodopa Or Carbidopa, Extended-Release Levodopa Or Carbidopa
2) By Dopamine Receptor Agonists: Pramipexole, Ropinirole, Rotigotine
3) By Monoamine Oxidase Type B (MAO-B) Inhibitors: Selegiline, Rasagiline, Safinamide
4) By Catechol-O-Methyltransferase (COMT)-Inhibitors: Entacapone, Tolcapone
5) By Anticholinergics: Benztropine, Trihexyphenidyl
6) By Other Drugs: Amantadine, Apomorphine
What Major Market Trends Are Driving Changes In The Anti-Parkinson Drugs Market?
Leading companies in the anti-Parkinson drugs market are focusing on developing advanced therapeutic solutions to address issues like motor fluctuations and dyskinesia, aiming to enhance symptom control and minimize side effects. Motor fluctuations and dyskinesia frequently complicate the treatment of Parkinson’s disease, impacting patient well-being. For instance, in January 2024, AbbVie Inc., a US-based pharmaceutical company, introduced PRODUODOPA. PRODUODOPA (foslevodopa/foscarbidopa) is the first subcutaneous 24-hour infusion therapy for advanced Parkinson’s disease, specifically targeting severe motor fluctuations and dyskinesia when other treatments have not been successful. It continuously delivers levodopa, potentially increasing “on” time and improving overall symptom control.
Who Are The Top Companies Competing In The Anti-Parkinson Drugs Market?
Major companies operating in the anti-parkinson drugs market are GlaxoSmithKline plc, Pfizer Inc., Novartis AG, F. Hoffmann-La Roche AG, UCB S.A, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Mylan NV, C.H. Boehringer Sohn AG & Co. KG, Orion Pharma Ltd., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., US WorldMeds LLC, Zydus Lifesciences Limited, Chemical Industrial & Pharmaceutical Laboratories Ltd., Strides Shasun Ltd., Upsher-Smith Laboratories LLC, H. Lundbeck A/S, Vertical Pharmaceuticals LLC, Zambon SPA, Valeant Pharmaceuticals International Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc.
Read the full anti-parkinson drugs market report here:
https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report
Which Geographic Regions Are Influencing Demand In The Anti-Parkinson Drugs Market?
North America was the largest region in the anti-Parkinson drugs market in 2025. Middle East is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in the anti-parkinson drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Anti-Parkinson Drugs Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=3462&type=smp
Browse Through More Reports Similar to the Global Anti-Parkinson Drugs Market 2026, By The Business Research Company
Anti Parkinson Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report
Neurological Disorder Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report
Anticholinergic Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/anticholinergic-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model